JPRN-UMIN000022254已完成2 期
Phase II Clinical Trial of Dasatinib Therapy Aiming for Treatment-Free Remission in Patients with Chronic Phase Chronic Myeloid Leukemia - Dasatinib Therapy Aiming for TFR in Patients with CML-CP (D-FREE)
Kanto CML Study Group0 个研究点目标入组 181 人开始时间: 2016年5月21日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 181
研究概览
简要总结
The study examined whether CML-CP patients (pts) treated with dasatinib (DAS) for <=3 years (yrs) and maintained MR4.5 for exactly 1 year (yr) would achieve TFR if DAS was discontinued. Of the first 21 pts who discontinued, 17 developed molecular relapse. The median duration of treatment with DAS before cessation was 18.9 months, which was shorter than previously reported. These results indicate that maintaining MR4.5 for 1 yr is not sufficient to achieve TFR in CML-CP pts treated with DAS for <= 3 yrs.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Active multiple cancers 2)Pregnant women and lactating mothers 3)Women who do not intend to or cannot use appropriate contraceptives during the registration period 4)Patients with a history or complications of the following severe or uncontrollable symptoms Myocardial infarction within the past 6 months Angina pectoris within the past 3 months Gastrointestinal haemorrhage within the past 3 months Congestive cardiac failure within the past 3 months Having plural effusion Electrocardiogram QTc interval prolonged exceeding 450 msec at the start of treatment (baseline) (Fridericia correction) Present or past history of pulmonary hypertension 5)Patients with a history or complications of diseases judged as inappropriate for study implementation by investigators.
研究者
相似试验
已完成
2 期
Dasatinib Therapy Aiming for TFR in Patients with CML-CPchronic myeloid leukemia in chronic phaseJPRN-jRCTs031180332Yoshida Chikashi181
已完成
不适用
A Study of Dasatinib Management Among CP-CML (Chronic Phase, Chronic Myeloid Leukemia) Participants Initiating Dasatinib in a Real Life SettingChronic Myeloid LeukemiaNCT04089839Bristol-Myers Squibb177
已完成
不适用
Phase II study of dasatinib for CML-CP patients with suboptima/failure after treatment of imatinibJPRN-UMIN000004280Fukuoka CML stem cell research group20
已完成
2 期
Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaLeukemiaNCT00982488Bristol-Myers Squibb238
已完成
不适用
Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry StudyLeukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT02389972Bristol-Myers Squibb128